This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saussy, D. L. Articles by Halushka, P. V. Search for Related Content PubMed PubMed Citation Articles by Saussy, D. L., Jr Articles by Halushka, P. V.

Circulation, Vol 72, 1202-1207, Copyright © 1985 by American Heart Association

ARTICLES

Thromboxane A2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle

DL Saussy Jr, DE Mais, DR Knapp and PV Halushka

9,11-Dimethylmethano-11,12-methano-16-(3-iodo-4-hydroxyphenyl)-13, 14- dihydro-13-aza-15 alpha beta-omega-tetranor-TXA2 (I-PTA-OH), a recently synthesized thromboxane (TX) A2/prostaglandin (PG) H2 receptor antagonist, was shown to be a competitive antagonist of human platelet aggregation induced by the stable endoperoxide analog U46619. This antagonism was due to competitive blockade of the platelet TXA2/PGH2 receptor since I-PTA-OH did not antagonize the first phase of ADP- induced aggregation which is TXA2/PGH2 independent, nor did it inhibit TXA2 synthesis. In addition, analysis of dose-response curves to U46619 (0.1 to 40 microM) in the presence of increasing concentrations of I- PTA-OH (0.5 to 10 microM) showed that I-PTA-OH produced a parallel rightward shift of the dose-response curve. Further analysis of the data in the form of a Schild plot yielded a straight line with a slope (m = 1.03) not significantly different from -1. These results are consistent with the notion that I-PTA-OH acts as a competitive antagonist of the TXA2/PGH2 receptor.

This article has been cited by other articles:

				B. L. Hodnett, J. A. Dearman, C. B. Carter, and R. L. Hester Attenuated PGI2 synthesis in obese Zucker rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2009; 296(3): R715 - R721. [Abstract] [Full Text] [PDF]

				J. Hanson, S. Rolin, D. Reynaud, N. Qiao, L. P. Kelley, H. M. Reid, F. Valentin, J. Tippins, B. T. Kinsella, B. Masereel, et al. In Vitro and in Vivo Pharmacological Characterization of BM-613 [N-n-Pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 293 - 301. [Abstract] [Full Text] [PDF]